Program
cabozantinib
Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.
Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.
Drug pageCabozantinib: every studyMany companies study it; this page follows only the 33 they lead. All 223 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixis | 237 open or running | phase 4since Jul 8, 2013 | Sep 20, 2005 | May 31, 2030phase 3 · NCT07620574 |
| Bristol-Myers Squibbits history only | 51 open or running | phase 3since May 3, 2017 | Nov 24, 2009 | Aug 25, 2029phase 2 · NCT03899155 |
| Ipsenits history only | 20 open or running | phase 2since May 9, 2019 | May 9, 2019 | none ahead |
| Takedaits history only | 20 open or running | phase 2since Nov 8, 2017 | Nov 8, 2017 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Apr 23, 2018 | Apr 23, 2018 | none ahead |
Also a collaborator on its studies: Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Roche-Genentech and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Exelixis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Sep 20, 2005.
- Jan 13, 2012Phase 3 study in Prostatic NeoplasmsNCT01522443 · 119 enrolled · United States, Australia, Canada and more
- Mar 9, 2012Phase 1 study in NeoplasmsNCT01553656 · 85 enrolled · Japan
- May 22, 2012Phase 3 study in Prostatic NeoplasmsNCT01605227 · 1,028 enrolled · United States, Australia, Austria and more
- Jan 3, 2013Phase 1 study in Renal InsufficiencyNCT01761773 · 32 enrolled · United States
- May 21, 2013Phase 3 study in Carcinoma, Renal CellNCT01865747 · 658 enrolled · United States, Argentina, Australia and more
- Jul 8, 2013Phase 4 study in Carcinoma, MedullaryNCT01896479 · 247 enrolled · Australia, Canada, Croatia and more
- Jul 23, 2013Phase 3 study in Carcinoma, HepatocellularNCT01908426 · 707 enrolled · United States, Australia, Belgium and more
- Nov 14, 2013Phase 2 study in Prostatic NeoplasmsNCT01995058 · 54 enrolled · United States
- May 23, 2017Phase 1 study in Carcinoma, Transitional CellNCT03170960 · 914 enrolled · United States, Australia, Belgium and more
- Sep 26, 2018Phase 3 study in Thyroid Cancer, PapillaryNCT03690388 · 187 enrolled · United States, Argentina, Australia and more
- Nov 26, 2018Phase 3 study in Carcinoma, HepatocellularNCT03755791 · 837 enrolled · United States, Argentina, Australia and more
- May 2, 2019Phase 3 study in Carcinoma, Renal CellNCT03937219 · 855 enrolled · United States, Argentina, Australia and more
- Jun 22, 2020Phase 3 study in Prostatic NeoplasmsNCT04446117 · 575 enrolled · United States, Argentina, Australia and more
- May 27, 2026Phase 3 study in NeoplasmsNCT07620574 · 5,000 planned · United States
Ahead
- May 31, 2030Primary completion: phase 3 study in NeoplasmsNCT07620574
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zanzalintinibrule | Exelixis | phase 3 | 17 |
Studies
All 23 Exelixis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07620574Neoplasms · United States | 3 | By invitation | May 31, 2030 | 5,000 |
| NCT04446117Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 19, 2024 | 575 |
| NCT03937219Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 31, 2022 | 855 |
| NCT03755791Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 30, 2021 | 837 |
| NCT03690388Thyroid Cancer, Papillary · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 19, 2020 | 187 |
| NCT03170960Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 1 | Active, not recruiting | Feb 21, 2023 | 914 |
| NCT01995058Prostatic Neoplasms · United States | 2 | Terminated | Nov 2014 | 54 |
| NCT01908426Carcinoma, Hepatocellular · United States, Australia, Belgium and more | 3 | Completed | Oct 16, 2017 | 707 |
| NCT01896479Carcinoma, Medullary · Australia, Canada, Croatia and more | 4 | Active, not recruiting | Jul 15, 2020 | 247 |
| NCT01865747Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | May 22, 2015 | 658 |
| NCT01761773Renal Insufficiency · United States | 1 | Completed | Apr 2013 | 32 |
| NCT01605227Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Sep 2014 | 1,028 |
| NCT01553656Neoplasms · Japan | 1 | Completed | May 2015 | 85 |
| NCT01522443Prostatic Neoplasms · United States, Australia, Canada and more | 3 | Terminated | Oct 2014 | 119 |
| NCT01493869Healthy · United States | 1 | Completed | May 2014 | 26 |
| NCT01100619Thyroid Cancer, Papillary · United States | 1 | Completed | Aug 2012 | 40 |
| NCT01068782Glioblastoma · United States, Canada | 2 | Terminated | May 2011 | 19 |
| NCT00960492Glioblastoma · United States | 1 | Completed | Nov 2012 | 26 |
| NCT00940225Neoplasms · United States, Belgium, Israel and more | 2 | Completed | May 2013 | 730 |
| NCT00704730Thyroid Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Oct 2011 | 330 |
| NCT00704288Glioblastoma · United States | 2 | Completed | Jun 2012 | 222 |
| NCT00596648Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Aug 2, 2012 | 92 |
| NCT00215605Lymphoma · United States | 1 | Completed | Apr 2011 | 85 |
How it is read
Names in the registry
- “Cabozantinib”, 18 entries
- “cabozantinib”, 9 entries
- “XL184”, 6 entries
- “Cabozantinib tablets”, 2 entries
- “Cabozantinib (XL184) 140 mg”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 6 studies
- Carcinoma, Renal Cell, 5 studies
- Prostatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 4 studies
- Glioblastoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.